306 related articles for article (PubMed ID: 28947497)
21. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
22. RCC2 is a novel p53 target in suppressing metastasis.
Song C; Liang L; Jin Y; Li Y; Liu Y; Guo L; Wu C; Yun CH; Yin Y
Oncogene; 2018 Jan; 37(1):8-17. PubMed ID: 28869598
[TBL] [Abstract][Full Text] [Related]
23. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.
Singh S; Vaughan CA; Frum RA; Grossman SR; Deb S; Palit Deb S
J Clin Invest; 2017 May; 127(5):1839-1855. PubMed ID: 28394262
[TBL] [Abstract][Full Text] [Related]
24. SUMOylation of the GTPase Rac1 is required for optimal cell migration.
Castillo-Lluva S; Tatham MH; Jones RC; Jaffray EG; Edmondson RD; Hay RT; Malliri A
Nat Cell Biol; 2010 Nov; 12(11):1078-85. PubMed ID: 20935639
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
27. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
28. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
Ali A; Shah AS; Ahmad A
Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
[TBL] [Abstract][Full Text] [Related]
30. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
[TBL] [Abstract][Full Text] [Related]
31. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
Olotu FA; Soliman MES
J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
33. SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene.
Wang CM; Brennan VC; Gutierrez NM; Wang X; Wang L; Yang WH
J Cell Biochem; 2013 Mar; 114(3):589-98. PubMed ID: 22991139
[TBL] [Abstract][Full Text] [Related]
34. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
35. Novel targets and interaction partners of mutant p53 Gain-Of-Function.
Aschauer L; Muller PA
Biochem Soc Trans; 2016 Apr; 44(2):460-6. PubMed ID: 27068955
[TBL] [Abstract][Full Text] [Related]
36. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
37. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
[TBL] [Abstract][Full Text] [Related]
38. Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage.
Park JH; Lee SW; Yang SW; Yoo HM; Park JM; Seong MW; Ka SH; Oh KH; Jeon YJ; Chung CH
Nat Commun; 2014 Nov; 5():5483. PubMed ID: 25406032
[TBL] [Abstract][Full Text] [Related]
39. Mutant p53-a potential player in shaping the tumor-stroma crosstalk.
Stein Y; Aloni-Grinstein R; Rotter V
J Mol Cell Biol; 2019 Jul; 11(7):600-604. PubMed ID: 31318969
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
